BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2024

Conditions
Hodgkin Lymphoma
Interventions
DRUG

BrentuximabVedotin (BV)

All patients will be treated with 6 cycles of BV-EPEM

Trial Locations (15)

Unknown

Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona

Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat

Hospital Costa del Sol, Marbella

Hospital Clinic i Provincial de Barcelona, Barcelona

Hospital Vall d'Hebron, Barcelona

Hospital de Basurto, Bilbao

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario La Paz, Madrid

Hospital Son Llatzer, Palma de Mallorca

Hospital Universitario de Salamanca, Salamanca

Hospital Universitario Donostia - Arantzazu, San Sebastián

Hospital Universitario Marqués de Valdecilla, Santander

Hospital Universitario Virgen del Rocío, Seville

Hospital Universitario Miguel Servet, Zaragoza

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

OTHER

NCT03576378 - BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | Biotech Hunter | Biotech Hunter